Product image of Levetiracetam Cinfa (Levetiracetam) supplied by GNH India

Levetiracetam Cinfa

Active Ingredient:
Levetiracetam
Origin:
EU

Levetiracetam Cinfa (Levetiracetam)

Levetiracetam, the active ingredient in Levetiracetam Cinfa, is an antiepileptic presented as an oral tablet for oral use. It is employed to control various seizure types in patients diagnosed with epilepsy.

GNH India supplies Levetiracetam Cinfa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Laboratorios Cinfa S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Levetiracetam Cinfa is an antiepileptic drug indicated for several seizure disorders. It helps reduce the frequency and severity of seizures in the following conditions:

  • Partial‑onset seizures: provides adjunctive control of focal seizures with or without secondary generalization.
  • Generalized tonic‑clonic seizures: reduces the occurrence of bilateral convulsive episodes.
  • Myoclonic seizures: diminishes rapid, brief muscle jerks characteristic of this seizure type.

How It Works

  • Levetiracetam binds selectively to the synaptic vesicle protein SV2A, a key regulator of neurotransmitter release. This interaction modulates vesicle exocytosis, stabilising neuronal membranes and decreasing hyper‑excitability, which in turn lowers the likelihood of seizure generation and propagation.

Side Effects

Levetiracetam may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects

  • Dizziness: transient sensation of light‑headedness.
  • Fatigue: generalized tiredness or lack of energy.
  • Somnolence: increased sleepiness during the day.
  • Headache: mild to moderate cranial pain.
  • Irritability: mood changes including agitation.
  • Nausea: occasional stomach upset.

Serious or Rare Side Effects

  • Severe allergic reactions: rash, swelling, or anaphylaxis.
  • Stevens‑Johnson syndrome: rare but serious skin disorder.
  • Blood dyscrasias: neutropenia or thrombocytopenia.
  • Suicidal thoughts: emergence of depressive or suicidal ideation.
  • Rash with systemic symptoms: may indicate a hypersensitivity reaction.
  • Depression: new or worsening mood disturbances.

Precautions & Warnings

Before initiating therapy, clinicians should consider several safety aspects.

  • Renal function: assess creatinine clearance and adjust dose if necessary.
  • Pregnancy: risk category is unknown; weigh potential benefits against unknown fetal risk.
  • Breastfeeding: evaluate infant exposure versus maternal benefit.
  • Concomitant CNS depressants: monitor for additive sedation.
  • Mood changes: observe for depression or suicidal ideation.
  • Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Levetiracetam has a relatively low interaction profile, but certain combinations require attention.

Major Interactions (Avoid)

  • Carbamazepine: may reduce levetiracetam plasma concentrations.
  • Phenytoin: potential decrease in levetiracetam exposure.
  • Phenobarbital: can lower levetiracetam levels.

Moderate Interactions (Monitor Closely)

  • Alcohol: additive central nervous system depression.
  • Other antiepileptics (e.g., valproate): may increase sedation.
  • Antidepressants or antipsychotics: watch for mood alterations.
  • Sedating antihistamines: possible enhanced drowsiness.
  • Opioids: monitor for increased respiratory depression.

Frequently Asked Questions

Levetiracetam Cinfa is an oral antiepileptic medication prescribed to control partial‑onset seizures, generalized tonic‑clonic seizures, and myoclonic seizures. It is used as an adjunctive therapy in patients with epilepsy to reduce seizure frequency and improve overall neurological stability.

Levetiracetam binds to the synaptic vesicle protein SV2A, which plays a crucial role in neurotransmitter release. This binding modulates vesicle exocytosis, stabilises neuronal firing, and diminishes excessive neuronal excitability, thereby lowering the likelihood of seizure initiation and spread.

The dosage of Levetiracetam Cinfa is individualized by the prescribing clinician based on the patient’s age, renal function, seizure type, and response to therapy. The prescriber determines the appropriate starting dose and any subsequent titration schedule.

Levetiracetam’s pregnancy category is not definitively established, and data are limited. Clinicians should weigh the potential benefits to the mother against uncertain fetal risk. Breastfeeding is also not well studied; a risk‑benefit assessment is recommended before continuation.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and required import documentation.

Compared with older agents such as carbamazepine or valproate, levetiracetam has a simpler pharmacokinetic profile, fewer drug‑enzyme interactions, and does not require routine blood‑level monitoring. It is generally well tolerated, though some patients may experience mood changes, which are less common with many alternatives.

Levetiracetam Cinfa tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Protect the product from moisture, excessive heat and direct sunlight to maintain potency throughout its shelf life.

The medication is taken orally, usually as a whole tablet swallowed with water. It may be taken with or without food, according to the prescriber’s instructions. Consistent timing each day helps maintain stable blood concentrations.

Serious adverse events, though rare, include severe allergic reactions (e.g., anaphylaxis or Stevens‑Johnson syndrome), blood dyscrasias such as neutropenia, and emergence of suicidal thoughts or depressive symptoms. Patients should seek immediate medical attention if they notice rash, fever, mood changes, or signs of infection.

Individuals with known hypersensitivity to levetiracetam or any of the tablet’s excipients should avoid the product. Caution is advised in patients with severe renal impairment, as dose adjustment may be required, and in those with a history of psychiatric disorders where mood changes could be problematic.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Levetiracetam

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT